{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-061200","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.968945+00:00","generated_at":"2026-06-02T01:32:19.438082+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Acura gets $200K loan from controlling shareholder; warns bankruptcy possible if no new funds by early June","bullets":["AD Pharma loaned $200K on May 10; total principal now $5.62M at 5.25%, due June 30, 2024.","Accrued interest ~$310K; default rate rises to 7.5% after 5-day grace.","Without additional financing by early June 2024, Acura may scale back operations or seek bankruptcy protection.","AD Pharma directly owns ~65% of Acura common stock; Mr. Schutte (AD Pharma manager) owns ~13% directly.","Loan proceeds used for day-to-day operations; no assurance further funding will be available."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-061200","json":"https://secwatch.observer/filing/0001104659-24-061200.json","markdown":"https://secwatch.observer/filing/0001104659-24-061200.md","text":"https://secwatch.observer/filing/0001104659-24-061200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465924061200/0001104659-24-061200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465924061200/tm2414484d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:32:19.438082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88a104af49935914fe0c30d1b0d1f3399314f58b","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $200,000 with Abuse Deterrent Pharma, LLC at 5.25% maturing June 30, 2024.","evidence_excerpt":"On May 10, 2024 we received a $200,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”). This loan combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $5,619,279 with accrued interest of approximately $310,000, bears interest at 5.25%, and matures on June 30, 2024, at which time all principal and interest is due (“Note”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465924061200/0001104659-24-061200-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$200,000"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Maturity","value":"June 30, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}